Background : Previously we reported the inhibition of coronary restenosis with Abciximab(ReoPro?)-coated stent. This study investigated the clinical outcomes of patients with acute myocardial infarction (AMI) treated with ReoPro?-coated stents. Methods : We performed a prospective randomized trial to compare two types of stents for the revascularization in 96 patients [Group I (abciximab-coated stent): n=48, 57.1짹12.0 years, 41 male, and Group II (control stent): n=48, 58.4짹11.6 years, 39 male] with AMI. The primary end points were major adverse coronary events (MACE): cardiac death, myocardial infarction (AMI), target lesion revascularization (TLR), in-stent restenosis and late lumen loss at 1 year clinical and angiographic follow-up. Results : All stents were successfully deployed and patients were discharged without clinical events. Baseline clinical characteristics, baseline diameter stenosis and minimal luminal diameter were not different between the two groups. Stent size and length were not different between the two groups (3.38짹0.37 mm, 18.0짹2.4 mm in group I vs 3.31짹0.36 mm, 18.7짹3.7 mm in group II). There was one myocardial infarction and revascularization during hospital stay in group II. Follow-up coronary angiogram was done 70%. Diameter stenosis and late loss were significantly lower in the group I compared with group II (18.5짹5.5 % vs. 38.1짹6.2 %, p=0.021; and 0.39짹0.30 mm vs. 0.87짹0.47 mm; p=0.010, respectively). And, the restenosis rates were significantly lower in the group I (13.9 % vs. 35.5 %, p=0.037). During clinical follow-up for 1 year at 98% patients, there were two AMI, one death in group II and no AMI, death in group I. The TLR rates and total MACE of group I were relatively lower compared with group II [10.4 %(5/48) vs. 20.8 %(10/48); p=0.130 and 10.4 %(5/48) vs. 25.0 %(12/48), p=0.053, respectively]. Conclusion : The abciximab-coated stent was safe without stent thrombosis and may be effective in the prevention of coronary restenosis in AMI patients.